Jul 23, 2019 / 12:00PM GMT
Operator
Greetings. Welcome to Marinus PPD data webcast. (Operator Instructions).
Please note this conference is being recorded. I would now like to turn the conference over to Lisa Caperelli with IR. Thank you. You may begin.
Lisa M. Caperelli - Marinus Pharmaceuticals, Inc. - Executive Director of Investor & Strategic Relations
Thank you, Sherry. Good morning, everyone, and thank you for joining this conference call where we will review data from our Magnolia and Amaryllis Phase II clinical studies, evaluating ganaxolone treatment regimens in women with Postpartum Depression.
Participants on today's call are Dr. Scott Braunstein, Executive Chairman of Marinus; and Dr. Lorianne Masuoka, our Chief Medical Officer. Dr. Kimberly McCormick, our Head of Regulatory Affairs; and Edward Smith, our CFO, are also on the line and will be available to answer questions during the Q&A session.
There are slides accompanying today's call in order to access these slides, please log into the webcast that's accessible from the Investor Relations
Marinus Pharmaceuticals, Inc. - Special Call Transcript
Jul 23, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers